• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Lifshitz Law PLLC Announces Investigations of KLR, CFMS, TALS, and SGTX

    7/15/23 8:07:00 PM ET
    $CFMS
    $KLR
    $SGTX
    $TALS
    Industrial Specialties
    Health Care
    EDP Services
    Technology
    Get the next $CFMS alert in real time by email

    NEW YORK, July 15, 2023 (GLOBE NEWSWIRE) --

    Kaleyra, Inc. (NYSE:KLR)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of KLR to Tata Communications Limited for $7.25 per share in cash.

    If you are a KLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Conformis Inc. (NASDAQ:CFMS)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CFMS to Restor3d, Inc. for $2.27 per share in cash.

    If you are a CFMS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Talaris Therapeutics, Inc. (NASDAQ:TALS)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of TALS and Tourmaline Bio, Inc. Under the terms of the proposed merger, Tourmaline Bio, Inc. shareholders will receive a number of shares of TALS common stock calculated in accordance with the Exchange Ratio for each share of Tourmaline Bio, Inc. owned. Following the merger, pre-merger TALS shareholders are expected to own approximately 21.3% of the outstanding equity of the combined company.

    If you are a TALS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Sigilon Therapeutics, Inc. (NASDAQ:SGTX)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SGTX to Eli Lilly & Company for $14.92 per share in cash, plus one non-tradeable CVR of up to $111.64 for each share of SGTX common stock owned.

    If you are a SGTX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    ATTORNEY ADVERTISING.© 2023 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

    Contact:

    Joshua M. Lifshitz, Esq.

    Lifshitz Law PLLC

    Phone: 516-493-9780

    Facsimile: 516-280-7376

    Email: [email protected]



    Get the next $CFMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CFMS
    $KLR
    $SGTX
    $TALS

    CompanyDatePrice TargetRatingAnalyst
    Talaris Therapeutics Inc.
    $TALS
    10/20/2022$18.00Buy
    H.C. Wainwright
    Talaris Therapeutics Inc.
    $TALS
    7/5/2022$20.00 → $8.00Overweight → Equal-Weight
    Morgan Stanley
    Kaleyra Inc.
    $KLR
    5/10/2022$15.00 → $6.50Buy → Hold
    Craig Hallum
    Sigilon Therapeutics Inc.
    $SGTX
    12/23/2021$12.00 → $7.00Buy
    Canaccord Genuity
    Sigilon Therapeutics Inc.
    $SGTX
    12/1/2021$16.00 → $7.00Overweight
    Barclays
    Sigilon Therapeutics Inc.
    $SGTX
    11/30/2021$9.00 → $4.50Equal-Weight
    Morgan Stanley
    Sigilon Therapeutics Inc.
    $SGTX
    11/30/2021$15.00 → $4.00Buy → Hold
    Jefferies
    Talaris Therapeutics Inc.
    $TALS
    11/12/2021$21.00 → $22.00Outperform
    SVB Leerink
    More analyst ratings

    $CFMS
    $KLR
    $SGTX
    $TALS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mcdade Mark bought $3,250,000 worth of shares (100,000 units at $32.50) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      1/31/24 4:26:17 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kulkarni Sandeep Chidambar bought $67,960 worth of shares (4,000 units at $16.99), increasing direct ownership by 0.55% to 729,735 units (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      11/20/23 6:15:47 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thiara Parvinder bought $17,310 worth of shares (1,000 units at $17.31), increasing direct ownership by 1% to 83,782 units (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      11/20/23 6:14:25 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFMS
    $KLR
    $SGTX
    $TALS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

      Combined Company to Trade on Nasdaq Under Ticker "TRML"Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris' stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris' common stock to the stockholders of Tourmaline Bio, Inc. ("Tourmaline") pursuant to the terms of the Agreement and Plan of Merger, dated as of June 22, 2023, pursuant to which a direct wholly owned subsidiary of Talaris will merge with a

      10/17/23 5:47:44 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

      Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Tourmaline Bio, Inc. ("Tourmaline") pursuant to the Agreement and Plan of Merger, dated June 22, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.5118 per share of Talaris common stock, will be payable in cash. The exact amount of the sp

      10/6/23 5:09:00 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tata Communications completes acquisition of Kaleyra, a leading global CPaaS platform player

      NEW YORK and MUMBAI, India , Oct. 5, 2023 /PRNewswire/ -- Tata Communications, a global digital ecosystem enabler, today announces completion of the acquisition of Kaleyra, Inc. (NYSE:KLR). On 28th June 2023, Tata Communications had entered into a definitive agreement with Kaleyra, Inc. to acquire it through Tata Communications Limited. The transaction has now been completed upon receipt of the approval by Kaleyra's stockholders, necessary regulatory approvals, and fulfilment of other customary closing conditions. Under the terms of the agreement, Tata Communications Limited has paid an aggregate consideration of approximately $100 million in cash and assumed all of Kaleyra's outstanding de

      10/5/23 12:09:00 PM ET
      $KLR
      EDP Services
      Technology

    $CFMS
    $KLR
    $SGTX
    $TALS
    Leadership Updates

    Live Leadership Updates

    See more

    $CFMS
    $KLR
    $SGTX
    $TALS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CFMS
    $KLR
    $SGTX
    $TALS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CFMS
    $KLR
    $SGTX
    $TALS
    SEC Filings

    See more

    $CFMS
    $KLR
    $SGTX
    $TALS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Kaleyra Appointed by stc Bahrain As Exclusive Omnichannel Partner

      Kaleyra To Support stc Bahrain's Enterprise Customers With Digital and Innovation Services  NEW YORK, Sept. 21, 2023 /PRNewswire/ -- Kaleyra, Inc. (NYSE:KLR) (NYSE:KLR) ("Kaleyra" or the "Company"), a rapidly growing omnichannel business communications platform, announced today an exclusive partnership with stc Bahrain, a world-class digital enabler. As the exclusive provider of omnichannel services, Kaleyra will support stc Bahrain in delivering personalized, flexible communication to its customers and enabling enterprise brands to do the same. With Kaleyra's advanced CPaaS p

      9/21/23 8:05:00 AM ET
      $KLR
      EDP Services
      Technology
    • Kaleyra Announces Changes in Management Team

      Kaleyra announces changes in the management team: Nicola Junior Vitto departure and new appointment of Mauro Carobene NEW YORK, Aug. 11, 2023 /PRNewswire/ -- Kaleyra, Inc. (NYSE:KLR) (NYSE:KLR) ("Kaleyra" or the "Company"), an enterprise Communication Platform as a Service (CPaaS), announces certain management changes.  As previously disclosed, on June 28, 2023, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with Tata Communications Limited, a company listed on BSE Limited and National Stock Exchange of India Limited ("Tata Communications"),

      8/11/23 4:15:00 PM ET
      $KLR
      EDP Services
      Technology
    • Talaris Therapeutics Announces Leadership Transition

      BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris's Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned workforce reduction, as previously announced by the Company. "On behalf of the board, I would like to thank Scott for his unwavering commitment to patients and to Talaris over the past four and a half years," said Francois Nader, MD, Chairman of the Talaris Therapeutics Board of Directors. "I welcome M

      5/26/23 7:00:00 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mcdade Mark bought $3,250,000 worth of shares (100,000 units at $32.50) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      1/31/24 4:26:17 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Siegall Clay B

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      12/15/23 4:23:26 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Siegall Clay B

      3 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      12/15/23 4:21:42 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Talaris Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Talaris Therapeutics with a rating of Buy and set a new price target of $18.00

      10/20/22 7:24:56 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talaris Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Talaris Therapeutics from Overweight to Equal-Weight and set a new price target of $8.00 from $20.00 previously

      7/5/22 7:28:16 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kaleyra downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Kaleyra from Buy to Hold and set a new price target of $6.50 from $15.00 previously

      5/10/22 7:31:55 AM ET
      $KLR
      EDP Services
      Technology
    • Talaris Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Tourmaline Bio, Inc. (0001827506) (Filer)

      1/26/24 4:12:52 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Talaris Therapeutics Inc.

      424B5 - Tourmaline Bio, Inc. (0001827506) (Filer)

      1/26/24 4:08:02 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Talaris Therapeutics Inc.

      424B5 - Tourmaline Bio, Inc. (0001827506) (Filer)

      1/24/24 9:20:06 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      2/14/24 9:08:07 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Talaris Therapeutics Inc.

      SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)

      2/14/24 8:51:41 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      2/14/24 5:04:58 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CFMS
    $KLR
    $SGTX
    $TALS
    Financials

    Live finance-specific insights

    See more
    • Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

      Combined Company to Trade on Nasdaq Under Ticker "TRML"Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris' stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris' common stock to the stockholders of Tourmaline Bio, Inc. ("Tourmaline") pursuant to the terms of the Agreement and Plan of Merger, dated as of June 22, 2023, pursuant to which a direct wholly owned subsidiary of Talaris will merge with a

      10/17/23 5:47:44 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

      Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Tourmaline Bio, Inc. ("Tourmaline") pursuant to the Agreement and Plan of Merger, dated June 22, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.5118 per share of Talaris common stock, will be payable in cash. The exact amount of the sp

      10/6/23 5:09:00 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

      NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") announced today NYBCe's acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky. The acquisition of both locations, combined with NYBCe's Comprehensive Cell Solutions (CCS) vast cell sourcing and collection network, accelerates the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution for the continental United States (US), capable of serving the bi

      10/4/23 8:30:00 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care